Application of PTRHD1 as a target site for tumor immunotherapy

By using PTRHD1 as a target site for tumor immunotherapy, inhibiting its expression or activity, regulating the PGAM5/DRP1 axis function, and promoting tumor cell apoptosis and immune cell activation, the problem of poor efficacy of tumor immunotherapy in existing technologies is solved, and more efficient tumor treatment results are achieved.

CN123059072APending Publication Date: 2026-11-10SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611579247.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-12
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

The lack of effective gene targets in current tumor immunotherapy leads to poor immunotherapy efficacy, especially in solid tumors.

Method used

Using PTRHD1 as a target site for tumor immunotherapy, by inhibiting the expression of PTRHD1 protein or reducing its activity, the function of the PGAM5/DRP1 axis is regulated, promoting excessive mitochondrial division in tumor cells, leading to non-programmed necrotizing apoptosis, activating cytotoxic immune cells, and improving the tumor immune microenvironment.

Benefits of technology

It improved the response rate and efficacy of tumor immunotherapy, enhanced the killing power against tumor cells, promoted tumor cell apoptosis and immune system clearance, and significantly inhibited tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059072A_ABST
    Figure CN123059072A_ABST
Patent Text Reader

Abstract

This application relates to the field of oncology drug technology, and more particularly to the application of PTRHD1 as a target site for tumor immunotherapy. It provides an application of PTRHD1 as a target site for tumor immunotherapy, wherein the PTRHD1 protein contains the amino acid sequence shown in SEQ ID No. 1, or a protein with at least 85% amino acid sequence identity with SEQ ID No. 1. PTRHD1 can regulate the protein function of mitochondrial phosphatidylcholine 5 (PGAM5) and mitochondrial dynamin DRP1 to regulate mitochondrial division and cell death. Tumor cells lacking PTRHD1 therefore exhibit increased inflammatory immunogenicity. Therefore, using PTRHD1 as a target site for tumor immunotherapy, by targeting and inhibiting the expression of PTRHD1-related genes or encoded proteins, can effectively stimulate the body's anti-tumor immunity, and has broad applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application belongs to the field of oncology drug technology, and in particular relates to the application of PTRHD1 as a target site for tumor immunotherapy. Background Technology

[0002] Tumors are new growths formed by the proliferation of local tissue cells under the influence of various tumorigenic factors. They are broadly classified into benign and malignant tumors, with malignant tumors further divided into carcinomas originating from epithelial tissue and sarcomas originating from mesenchymal tissue. In recent years, tumor immunotherapy has become an important treatment paradigm following surgery, radiotherapy, and chemotherapy due to its potential to achieve long-term anti-tumor effects by activating the patient's own immune system. Immune checkpoint inhibitors, represented by PD-1 / PD-L1 inhibitors, and CAR-T therapy targeting CD19 have been successfully commercialized, achieving revolutionary progress in the treatment of various malignant tumors. However, current mainstream immunotherapies still have significant limitations: the objective response rate of immune checkpoint inhibitors is generally low, with less than 30% of patients benefiting from them. This is due to factors such as the immunosuppressive state of the tumor microenvironment, immune recognition escape caused by defects in tumor cell antigen presentation, and high tumor heterogeneity. Furthermore, cell therapies such as CAR-T have limited efficacy in solid tumors, with the key obstacle being the heterogeneity of solid tumor antigens leading to a lack of universally safe attack targets, and the difficulty for immune cells to effectively infiltrate and persist in the immunosuppressive microenvironment. The above issues indicate that single immunotherapy methods are insufficient to completely overcome the multiple escape mechanisms of tumors, and the development of new immunotherapy targets is crucial for improving efficacy.

[0003] To improve efficacy and the number of responders, combination immunotherapy strategies have become a clear direction for development. The core of these strategies lies in synergistically enhancing the anti-tumor immune response through different mechanisms of action. The prerequisite for developing effective combination therapies is to systematically discover and validate more novel immunotherapeutic targets that can be intervened. Therefore, CRISPR-based gene function screening libraries, with their high throughput and systematic advantages, have become a core tool for optimizing immunotherapy regimens, mainly covering three application areas: First, in immune cell modification, CRISPR loss-of-function or gain-of-function screening systems can be used to identify key genes regulating T cell survival, proliferation, persistence, and killing activity on a large scale; Second, at the tumor cell level, whole-genome CRISPR screening can systematically reveal drug resistance mechanisms mediating immune escape, such as CD58 gene deletion disrupting immune synapse formation, and genes such as NUDT21 mediating antigen loss through transcriptional regulation; Third, in complex in vivo models, adeno-associated virus-mediated in vivo CRISPR screening platforms can be used to discover novel therapeutic targets in the real tumor immune microenvironment, such as screening the COP1 gene in a triple-negative breast cancer model and identifying the SUSD6 gene in an acute myeloid leukemia model.

[0004] However, existing technologies still lack gene targets to improve the efficacy of tumor immunotherapy, which affects the preparation and use of tumor immunotherapy drugs. Summary of the Invention

[0005] The purpose of this application is to provide an application of PTRHD1 as a target site for tumor immunotherapy, aiming to solve the problem of the lack of new gene targets to improve the efficacy of tumor immunotherapy in the existing technology, which in turn affects the preparation and use of tumor immunotherapy drugs.

[0006] To achieve the above-mentioned objectives, the technical solution adopted in this application is as follows: In a first aspect, this application provides an application of PTRHD1 as a target site for tumor immunotherapy, wherein the PTRHD1 protein comprises the amino acid sequence shown in SEQ ID No. 1, or a protein having at least 85% amino acid sequence identity with SEQ ID No. 1.

[0007] In some embodiments, the PTRHD1 protein further includes the amino acid sequence shown in SEQ ID No. 2.

[0008] In some embodiments, the PTRHD1 protein is encoded by the mouse mRNA sequence shown in SEQ ID No. 3 or the human mRNA sequence shown in SEQ ID No. 4.

[0009] In some embodiments, the application includes: using PTRHD1 as a tumor immunotherapy target to prepare a drug for the prevention or treatment of tumors.

[0010] In some embodiments, PTRHD1 is used as a tumor immunotherapy target to activate cytotoxic immune cells during immunotherapy.

[0011] In some embodiments, the cytotoxic immune cells include NK cells, CD8 cells, etc. + At least one of the following in T cells.

[0012] In some embodiments, the mechanism by which PTRHD1 is used as a tumor immunotherapy target for immunotherapy is as follows: by inhibiting PTRHD1 expression, the function of the PGAM5 / DRP1 axis is regulated, promoting excessive division of mitochondria in tumor cells, leading to unprogrammed necrosis and apoptosis of cells. The occurrence of tumor cell necrosis and apoptosis promotes the improvement of the tumor immune microenvironment, while enhancing the inflammatory immunogenicity of cells and thereby activating cytotoxic immune cells to exert their effects.

[0013] In some embodiments, the tumor includes a primary tumor and metastatic tumors.

[0014] Secondly, embodiments of this application provide a drug for tumor immunotherapy, wherein the drug is a drug that inhibits the expression of PTRHD1 protein or reduces the activity of PTRHD1 protein, wherein the PTRHD1 protein contains the amino acid sequence shown in SEQ ID No. 1, or has at least 85% amino acid sequence identity with SEQ ID No. 1.

[0015] In some embodiments, the drug comprises siRNA that targets the mRNA encoding the PTRHD1 protein and lipid nanoparticles that deliver the siRNA, constituting an siRNA-LNP complex.

[0016] In some embodiments, the siRNA includes chemical modifications selected from one or more of 2'-O-methyl modification, 2'-fluorine modification, thiophosphate bond modification, or 5'-terminal cholesterol modification.

[0017] In some embodiments, the lipid nanoparticles comprise ionizable cationic lipids, cofactor lipids, cholesterol, and polyethylene glycol-modified lipids.

[0018] The first aspect of this application provides the application of PTRHD1 as a target site for tumor immunotherapy. PTRHD1 is a novel mitochondrial quality control protein located in the mitochondria. Missense mutations (such as p.C52Y, p.R122W) and truncated mutations (such as frameshift deletions and nonsense mutations) in PTRHD1 can disrupt protein function and cause neurodevelopmental disorders with early-onset Parkinson's syndrome (NEDPBA). This is an autosomal recessive genetic disease, unlike simple early-onset PD such as PRKN, where intellectual disability is its core marker. Screening of a mouse immune stress library revealed that PTRHD1 is an ideal target for combined immunotherapy. Furthermore, PTRHD1 can regulate the function of PGAM5 / DRP1, promoting excessive mitochondrial division in tumor cells, leading to unprogrammed apoptosis. This apoptosis improves the tumor immune microenvironment and enhances inflammatory immunogenicity, thereby activating cytotoxic immune cells. Therefore, using PTRHD1 as a target site for tumor immunotherapy, by inhibiting the expression of PTRHD1-related genes or encoded proteins, can effectively stimulate the body's anti-tumor immunity, making PTRHD1 a target site that can enhance the response rate of tumor immunotherapy. This demonstrates the broad application prospects of using PTRHD1 as a tumor therapeutic target in anti-tumor immunotherapy.

[0019] The second aspect of this application provides a drug for tumor immunotherapy, wherein the drug is a drug that inhibits the expression of the PTRHD1 gene, inhibits the expression of the PTRHD1 protein, or reduces the activity of the PTRHD1 protein; by inhibiting the expression of PTRHD1-related genes or encoded proteins, the drug effectively stimulates the body's anti-tumor immunity and improves the efficacy of tumor immunotherapy. Attached Figure Description

[0020] To more clearly illustrate the technical solutions in the embodiments of this application, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0021] Figure 1 This is an analysis diagram showing that the CRISPRi / Cas9 library screening identified PTRHD1 as a novel therapeutic target for tumor immunotherapy, as provided in the embodiments of this application. Figure 2 This is an analysis diagram showing that inhibiting PTRHD1 can suppress tumor growth, provided in the embodiments of this application. Figure 3 This is an analysis diagram showing that inhibiting PTRHD1 can enhance the therapeutic effect of tumors against PD-1, provided in the embodiments of this application. Figure 4 This is an analysis diagram provided in the embodiments of this application showing that PTRHD1 deficiency can promote the infiltration of cytotoxic immune cells in the tumor microenvironment; Figure 5 This is a diagram illustrating the analysis of mitochondrial dysfunction and cell death induced by PTRHD1 gene deletion provided in the embodiments of this application; Figure 6 This is a graph showing the evaluation and analysis of the antitumor efficacy of the siRNA-LNP drug targeting the PTRHD1 gene combined with the PD-1 blocker provided in the embodiments of this application. Detailed Implementation

[0022] To make the technical problems, technical solutions, and beneficial effects of this application clearer, the following detailed description is provided in conjunction with embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the scope of this application.

[0023] In this application, the term "and / or" describes the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, or B existing alone. A and B can be singular or plural. The character " / " generally indicates that the preceding and following related objects have an "or" relationship.

[0024] In this application, "at least one" means one or more, and "more than one" means two or more. "At least one of the following" or similar expressions refer to any combination of these items, including any combination of single or multiple items. For example, "at least one of a, b, or c", or "at least one of a, b, and c", can both mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, and c can be single or multiple.

[0025] It should be understood that in the various embodiments of this application, the order of the above processes does not imply the order of execution. Some or all steps may be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of this application.

[0026] The terminology used in the embodiments of this application is for the purpose of describing particular embodiments only and is not intended to be limiting of this application. The singular forms "a" and "the" as used in the embodiments of this application and the appended claims are also intended to include the plural forms, unless the context clearly indicates otherwise.

[0027] The weights of the relevant components mentioned in the embodiments of this application can refer not only to the specific content of each component, but also to the proportional relationship between the weights of the components. Therefore, any scaling up or down of the content of the relevant components according to the embodiments of this application is within the scope disclosed in the embodiments of this application. Specifically, the mass described in the embodiments of this application can be a well-known unit of mass in the chemical industry, such as µg, mg, g, or kg.

[0028] The terms "first" and "second" are used for descriptive purposes only, to distinguish objects, such as substances, from one another, and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. For example, without departing from the scope of the embodiments of this application, "first XX" may also be referred to as "second XX," and similarly, "second XX" may also be referred to as "first XX." Thus, features defined with "first" and "second" may explicitly or implicitly include one or more of that feature.

[0029] The first aspect of this application provides an application of PTRHD1 as a target site for tumor immunotherapy, wherein the PTRHD1 protein contains the amino acid sequence shown in SEQ ID No. 1, or a protein having at least 85% amino acid sequence identity with SEQ ID No. 1.

[0030] The application of PTRHD1 as a target site for tumor immunotherapy, as provided in the first aspect of this application, involves PTRHD1, a novel mitochondrial-localized mitochondrial quality control protein. Missense mutations (such as p.C52Y and p.R122W) and truncated mutations (such as frameshift deletions and nonsense mutations) in PTRHD1 can disrupt protein function, leading to neurodevelopmental disorders with early-onset Parkinson's syndrome (NEDPBA). This is an autosomal recessive genetic disease, unlike simple early-onset PD such as PRKN, where intellectual disability is its core marker. Screening of a mouse immune stress library revealed that PTRHD1 is an ideal target for combined immunotherapy. Furthermore, PTRHD1 was found to regulate the function of the PGAM5 / DRP1 axis, promoting excessive mitochondrial division in tumor cells, leading to unprogrammed apoptosis. This apoptosis improves the tumor immune microenvironment and enhances inflammatory immunogenicity, thereby activating cytotoxic immune cells. Therefore, using PTRHD1 as a target site for tumor immunotherapy, by inhibiting the expression of PTRHD1-related genes or encoded proteins, can effectively stimulate the body's anti-tumor immunity, making PTRHD1 a target site that can enhance the response rate of tumor immunotherapy. This demonstrates the broad application prospects of using PTRHD1 as a tumor therapeutic target in anti-tumor immunotherapy.

[0031] In some embodiments, the amino acid sequence shown in SEQ ID No. 1 is the amino acid sequence of mouse-derived PTRHD1, as follows: MHRKVRPASLMIRKMACSGVEPQILVQYLVLRKDLSQAPFSWPTGALVAQACHAATAALHLHRDHPHTAAYLRELGRMRKVVLEAADETTLKELAETLQQKNIDHTLWLEQPENIATCIALRPYPKEEVSQYLKKFRLFK.

[0032] In some embodiments, the PTRHD1 protein further includes the amino acid sequence shown in SEQ ID No. 2. The amino acid sequence shown in SEQ ID No. 2 is a human-derived amino acid sequence, as follows: MHRGVGPAFRVVRKMAASGAEPQVLVQYLVLRKDLSQAPFSWPAGALVAQACHAATAALHTHRDHPHTAAYLQELGRMRKVVLEAPDETTLKELAETLQQKNIDHMLWLEQPENIATCIALRPYPKEEVGQYLKKFRLFK.

[0033] In some embodiments, the PTRHD1 protein is encoded by the mouse mRNA sequence shown in SEQ ID No. 3 or the human mRNA sequence shown in SEQ ID No. 4.

[0034] In some embodiments, the base sequence of the mouse mRNA sequence is as shown in SEQ ID No. 3, which specifically is:

[0035] In some embodiments, the base sequence of the human mRNA sequence is as shown in SEQ ID No. 4, which specifically is:

[0036] In some embodiments, PTRHD1 is used as a target site for tumor immunotherapy. During application, it enhances the killing effect on tumor cells by combining immune checkpoint therapy, including the killing effect of cytokines or combinations of cytokines on tumor cells and the killing effect of immune cells on tumor cells. Among them, immune cells include tumor killing cells such as CTL, TH, and NK, and factors include FasL, TNFα, IFNγ, or IFNβ. The combination of cytokines includes two or more of FasL, TNFα, IFNγ, and IFNβ.

[0037] In some embodiments, the application of PTRHD1 as a target site for tumor immunotherapy can help inhibit tumor cell growth by targeting PTRHD1. Inhibition of tumor cell growth includes promoting tumor cell apoptosis, inhibiting tumorigenesis, and allowing tumor cells to be cleared by the immune system.

[0038] In some embodiments, the application includes: using PTRHD1 as a tumor immunotherapy target to prepare drugs for the prevention or treatment of tumors. Because using PTRHD1 as a tumor immunotherapy target can promote the development of tumor immunotherapy-related drugs, the developed drugs for the prevention or treatment of tumors can effectively stimulate the body's anti-tumor immunity by inhibiting PTRHD1 expression, affecting non-programmed apoptosis of cells, and making PTRHD1 a target site that can enhance the response rate of tumor immunotherapy. Therefore, using PTRHD1 as a tumor treatment target has broad application prospects in anti-tumor immunotherapy.

[0039] In some embodiments, PTRHD1 is used as a tumor immunotherapy target to activate cytotoxic immune cells during immunotherapy.

[0040] In some embodiments, the cytotoxic immune cells include NK cells, CD8 cells, etc. + At least one of the following in T cells.

[0041] In some embodiments, the mechanism by which PTRHD1 is used as a tumor immunotherapy target for immunotherapy is as follows: by inhibiting PTRHD1 expression, the function of the PGAM5 / DRP1 axis is regulated, promoting excessive division of mitochondria in tumor cells, leading to unprogrammed necrosis and apoptosis of cells. The occurrence of tumor cell necrosis and apoptosis promotes the improvement of the tumor immune microenvironment, while enhancing the inflammatory immunogenicity of cells and thereby activating cytotoxic immune cells to exert their effects.

[0042] In some embodiments, the dosage form of the drug is selected from at least one of tablets, capsules, granules, pills, injections, suspensions, dispersants, and syrups. However, the dosage form of the drug of the present invention is not limited to this, and other achievable dosage forms are within the scope of protection of the present invention.

[0043] In some embodiments, the medicament further includes pharmaceutical excipients. The addition of pharmaceutically acceptable excipients to the medicament ensures the preparation and clinical application of the resulting medicament. In some specific embodiments, the pharmaceutical excipients are selected from at least one of diluents, wetting agents, binders, lubricants, colorants, and coating agents. In some embodiments, the addition of diluents is primarily for increasing the weight and volume of the medicament to facilitate shaping and dispensing. In a preferred embodiment of the invention, the diluent is selected from, but not limited to, at least one of starch, pregelatinized starch, dextrin, sucrose, lactose, mannitol, and microcrystalline cellulose. In some embodiments, the addition of wetting agents wets the material to produce sufficient viscosity to facilitate granulation. In a preferred embodiment of the invention, the wetting agent is selected from, but not limited to, at least one of water, ethanol, and glycerol. In some embodiments, the addition of binders aggregates and binds non-viscous or less viscous materials into granules. In a preferred embodiment of the invention, the binder is selected from, but not limited to, at least one of hydroxypropyl methylcellulose (HPMC), povidone (PVP), starch paste, and syrup. In some embodiments, coating agents and colorants are added to improve tablet appearance, increase drug stability, mask unpleasant drug odor, and alter particle appearance. In a preferred embodiment of the invention, the coating agent is selected from, but is not limited to, at least one of acrylic resin, hydroxypropyl methylcellulose, povidone, and cellulose acetate; the colorant is selected from, but is not limited to, at least one of titanium dioxide, sunset yellow, and methylene blue.

[0044] In some embodiments, the tumor includes a primary tumor and metastatic tumors.

[0045] In some embodiments, the tumor includes at least one of melanoma, breast cancer, pancreatic cancer, liver cancer, colon cancer, and lung cancer.

[0046] A second aspect of this application provides a drug for tumor immunotherapy, wherein the drug is a drug that inhibits the expression of PTRHD1 protein or reduces the activity of PTRHD1 protein, wherein the PTRHD1 protein contains the amino acid sequence shown in SEQ ID No. 1, or has at least 85% amino acid sequence identity with SEQ ID No. 1.

[0047] The second aspect of this application provides a drug for tumor immunotherapy, which is a drug that inhibits the expression of the PTRHD1 gene, inhibits the expression of the PTRHD1 protein, or reduces the activity of the PTRHD1 protein; by inhibiting the expression of PTRHD1-related genes or encoded proteins, the drug effectively stimulates the body's anti-tumor immunity and improves the effect of tumor immunotherapy.

[0048] In some specific embodiments, the drug further includes inhibiting the expression of the PTRHD1 gene by gene editing to cause base insertion mutations, base deletion mutations, non-synonymous base mutations, or complete gene loss in the PTRHD1 gene.

[0049] In a specific implementation, based on a comprehensive comparison of drug stability, in vivo delivery efficiency, and gene silencing effect, small interfering RNA (siRNA) is used as a regulator targeting the target PTRHD1, and lipid nanoparticles (LNPs) are used as its delivery carrier to construct an siRNA-LNP complex. This complex, administered systemically or locally, can efficiently deliver siRNA to tumor tissues, specifically knocking down the expression of the target PTRHD1 within tumor cells. This induces a cascade of excessive mitochondrial division, inflammation, and necrosis-apoptosis in vivo, achieving "sensitization" of tumor cells.

[0050] In some embodiments, the drug comprises siRNA that targets mRNA encoding the PTRHD1 protein and lipid nanoparticles that deliver the siRNA, constituting an siRNA-LNP complex.

[0051] In some embodiments, the siRNA includes chemical modifications selected from one or more of 2'-O-methyl modification, 2'-fluorine modification, thiophosphate bond modification, or 5'-terminal cholesterol modification.

[0052] In some embodiments, the lipid nanoparticles comprise ionizable cationic lipids, cofactor lipids, cholesterol, and polyethylene glycol-modified lipids.

[0053] In some embodiments, in established mouse tumor models, administration of immune checkpoint inhibitors (such as anti-PD-1 antibodies) alone produces only limited tumor-suppressing effects. However, when combined with the administration of a siRNA-LNP complex targeting PTRHD1, a significant synergistic anti-tumor effect is observed, manifested as strong inhibition or even partial regression of tumor growth.

[0054] Further immunological analysis showed that in the tumor microenvironment of the combined treatment group, the infiltration rate of cytotoxic T lymphocytes and the expression of activation markers were significantly upregulated, while the levels of immunosuppressive cytokines decreased. This confirms the feasibility and superiority of combining "targeting PTRHD1 to silence sensitized tumor cells" with "blocking immune checkpoints to activate the immune system".

[0055] In some embodiments, the immune checkpoint inhibitor is an anti-PD-1 antibody.

[0056] In some embodiments, the formulation that downregulates or inhibits the target PTRHD1 is administered simultaneously with the immune checkpoint inhibitor.

[0057] In some embodiments, the siRNA-LNP complex is administered via intratumoral injection.

[0058] In some embodiments, the immune checkpoint inhibitor is administered via intraperitoneal injection.

[0059] In some embodiments, the siRNA-LNP complex, wherein the LNP comprises ionizable cationic lipids, auxiliary lipids, cholesterol, and PEGylated lipids.

[0060] In some embodiments, the ionizable cationic lipid is selected from DLin-MC3-DMA, SM-102, or ALC-0315.

[0061] In some embodiments, the dosage of the siRNA-LNP complex is 0.1 mg to 10 mg siRNA per kilogram of body weight, and the dosage of the immune checkpoint inhibitor is 10% to 100% of its clinically approved monotherapy dose.

[0062] In some embodiments, the siRNA-LNP complex is administered on days 9, 12, 15, and 18, and the immune checkpoint inhibitor is administered on days 6, 9, 12, 15, and 18.

[0063] The following description is based on specific embodiments.

[0064] Example 1 To systematically screen potential targets that can enhance the efficacy of tumor immunotherapy in vivo, a functional screening platform based on CRISPR-Cas9 gene editing technology was constructed.

[0065] The specific experimental steps are as follows: 1. CRISPR mixed library construction and cell line preparation 1.1. The mouse melanoma cell line B16-F10 was selected as the research subject.

[0066] 1.2. Design and synthesize corresponding sgRNA sequence libraries for small gene libraries whose functions are not yet clearly defined.

[0067] 1.3. The sgRNA library sequence was cloned into a lentiviral vector, and high-quality viral particles were prepared using a lentiviral packaging system.

[0068] 1.4. B16-F10 cells were cultured in vitro and infected with lentiviruses according to standard procedures to ensure a low multiplicity of infection (MOI≈0.3) so that each cell integrates only one sgRNA, thus constructing a mixed library of tumor cells containing multiple gene knockouts.

[0069] 1.5. Cell populations that successfully integrate sgRNA were enriched through drug screening (such as puromycin), expanded and cultured, and used as tumor cell libraries for screening.

[0070] 2. Establishment of in vivo screening models and tumor transplantation The constructed tumor cell hybrid library was subcutaneously transplanted into various mouse models to simulate different immune stress environments (see illustration for specific grouping design). Figure 1 ): 2.1. In vitro baseline group: A portion of the mixed library cells were cultured under standard in vitro culture conditions (e.g., 37°C, 5% CO2) as the initial control for screening to determine the abundance distribution of initial sgRNA.

[0071] 2.2. Immunodeficiency model group: The cell library was prepared in a predetermined quantity (e.g., 5 × 10⁻⁶). 5 (1 mouse / mouse) was injected subcutaneously into nude mice. Nude mice lack T-cell-mediated adaptive immunity, and this model was used to exclude non-immune-dependent genetic effects.

[0072] 2.3. Immune-intact model group: The cell library was subcutaneously inoculated into wild-type C57BL / 6 mice in the same quantity. This model was used to simulate stress on the intact immune system.

[0073] 2.4. Immunotherapy Model Group: The cell library was subcutaneously inoculated into another group of wild-type C57BL / 6 mice in the same quantity. After the tumor became palpable, anti-PD-1 antibodies were administered via intraperitoneal injection according to a predetermined protocol (e.g., dosage, frequency). This model aims to screen for targets whose absence under immune checkpoint blockade pressure can enhance therapeutic sensitivity.

[0074] 3. Screening endpoint sample collection, library construction, and sequencing 3.1. After the tumors in each experimental group of mice grew to the predetermined endpoint volume (e.g., the long diameter of about 1.5 cm) or at the predetermined time point, the mice were sacrificed and the tumor tissue was aseptically dissected.

[0075] 3.2. Total genomic DNA (gDNA) was extracted from each tumor tissue and in vitro baseline cells using a genomic DNA extraction kit.

[0076] 3.3. Using gDNA as a template, specific primers were used to amplify the sgRNA sequence integrated into the genome by PCR.

[0077] 3.4. The PCR products were purified and a sequencing library was constructed. High-throughput deep sequencing was then performed to obtain the sequences and abundance information of all sgRNAs in each sample.

[0078] 4. Data Analysis and Target Identification 4.1. The sequencing data were analyzed using algorithms such as MAGeCK v3.0 to compare the changes in sgRNA abundance among the “immunotherapy model group”, “immunely healthy model group”, “immunodeficiency model group”, and “in vitro baseline group”.

[0079] 4.2. Focus on sgRNAs that are significantly depleted (i.e., significantly reduced in abundance) in the "immunotherapy model group". The screening criterion is that the abundance of the sgRNA under anti-PD-1 treatment stress must be significantly lower than its abundance in immune-healthy and immunodeficient environments.

[0080] 4.3. Through multiple rounds of biological replication and bioinformatics analysis, the gene targeted by the candidate sgRNA was identified. The gene PTRHD1 was ultimately identified. Its data characteristics indicate that knocking out the PTRHD1 gene specifically enhances tumor sensitivity to PD-1 therapy, and this effect depends on the presence of the immune system.

[0081] Figure 1 This is a graph showing the results of CRISPRi / Cas9 library screening that identified PTRHD1 as a novel target for tumor immunotherapy. Figure 1 It can be seen that the abundance of sgRNA targeting the PTRHD1 gene is significantly reduced (depleted) under the pressure of anti-PD-1 therapy, indicating that the deletion of the PTRHD1 gene can specifically enhance the sensitivity of tumors to anti-PD-1 therapy, and this effect depends on the presence of the immune system.

[0082] in, Figure 1 'a' is a Venn diagram showing the intersection of significantly depleted genes in pairwise comparisons of the three groups: "isotype control group and anti-PD-1 treatment group", "nude mouse group and isotype control group", and "nude mouse group and anti-PD-1 treatment group". A total of 28 intersection genes were obtained, including PTRHD1, WDR43, Mien1, Fam186b, and Nlx1-1. Figure 1b is a scatter plot of RRA scores and p-values ​​for each candidate gene in the “Isotype vs Anti-PD-1” comparison. Ptrhd1 (marked in red) is shown together with genes such as Csn3, Gskip, Vprbp, Kmt2d, Fbl, Siah1b, Wdr43, and Fam186b. Ptrhd1 is located in a significantly depleted region. Figure 1 c represents the Log2 fold change distribution of Ptrhd1sgRNAs and its abundance change location in the three comparison groups above. It shows that Ptrhd1sgRNAs are mainly distributed on the "change (depletion)" side in each group, and the depletion is most significant in the comparison group with anti-PD-1 treatment pressure.

[0083] Example 2 To verify the reliability of the high-throughput screening results and to further explore the specific functional mechanism of the PTRHD1 gene under different immune backgrounds, this embodiment conducted systematic in vitro and in vivo biological experiments.

[0084] The specific experimental steps are as follows: 1. Construction of stable PTRHD1 gene knockout transgenes in multi-species / multi-type tumor cell lines 1.1. Cell line selection: Human melanoma cell line A375, mouse melanoma cell line B16-F10, mouse pancreatic cancer cell line Panc02, and mouse breast cancer cell line 4T1 were selected as research subjects to verify the universality of PTRHD1 gene function.

[0085] 1.2. sgRNA Design and Vector Construction: Specific sgRNAs were designed and synthesized targeting specific exon sequences of the PTRHD1 gene. The sgRNA sequences were cloned into lentiviral vectors carrying Cas9 and resistance markers (such as puromycin).

[0086] 1.3. Viral Packaging and Cell Infection: HEK293T cells were co-transfected with packaging plasmids to produce lentiviral particles carrying a CRISPR vector. The harvested virus was then used to infect target cell lines (A375, B16-F10, Panc02, 4T1).

[0087] 1.4. Screening of stable cell lines: 48-72 hours after viral infection, add the corresponding antibiotic (such as puromycin) for pressure screening, and continue culturing for 1-2 weeks to obtain a pool of resistant cells. Obtain monoclonal cell lines by limiting dilution or flow cytometry.

[0088] 1.5. Knockout efficiency verification: a. Protein level validation: Lysates of monoclonal cells were collected and analyzed by Western blotting to detect PTRHD1 protein expression. Compared with control cells transduced with empty vector (Ctrl), PTRHD1 protein expression was confirmed to be significantly reduced or completely absent in knockout cells (PTRHD1-KO).

[0089] 2. In vitro detection of non-immune-dependent phenotypes of tumor cells To assess the impact of PTRHD1 gene deletion on the basic biological functions of tumor cells, the following experiments were conducted under standard culture conditions: 2.1. Cell proliferation experiment: a. Logarithmically growing B16-F10 and Panc02 Ctrl cells were seeded in the same number as PTRHD1-KO cells in multi-well plates.

[0090] b. At subsequent designated time points (e.g., 1, 2, 3), use a cell counting kit to directly count and determine the number of viable cells.

[0091] c. Plot cell growth curves and compare the proliferation rates of the two groups of cells.

[0092] 2.2. Plate colony formation experiment: a. Seed B16-F10 and Panc02 Ctrl and PTRHD1-KO cells at a low density (e.g., 500 cells / dish) in culture dishes.

[0093] b. Incubate at 37°C and 5% CO2 for 7-14 days, changing the culture medium regularly.

[0094] c. Once visible cell clones appear, discard the culture medium, fix the cells with methanol, and stain with Giemsa.

[0095] d. Count the number of clones containing more than 50 cells, calculate the colony formation rate, and compare the differences between groups.

[0096] 3. Verification of in vivo tumor-suppressive effect and immune dependence By comparing immune-healthy and immunodeficient mouse models, this study verifies whether the in vivo effects of PTRHD1 gene knockout depend on the immune system.

[0097] 3.1. Immunocompact mouse model experiment: a. Animal grouping and inoculation: Immunologous mice were randomly divided into two groups. The experimental group was subcutaneously inoculated with PTRHD1-KO tumor cells (B16-F10, Panc02 or 4T1), while the control group was subcutaneously inoculated with the corresponding Ctrl tumor cells.

[0098] b. Tumor monitoring: Regularly measure the major diameter (L) and minor diameter (W) of the tumor using calipers, calculate the tumor volume using the formula (volume = L × W² / 2), and plot the tumor growth curve.

[0099] c. Endpoint analysis: When the experimental endpoint is reached, the tumor is removed and weighed, and the final tumor volume and weight are compared between the two groups.

[0100] 3.2. Immunodeficient mouse model (nude mouse) experiment: a. Animal grouping and inoculation: T-cell-deficient nude mice were randomly divided into two groups. One group was subcutaneously inoculated with B16-F10Ctrl cells, and the other group was inoculated with B16-F10 PTRHD1-KO cells.

[0101] b. Tumor monitoring and endpoint analysis: Using the same methods as in steps 3.1.b and 3.1.c, the tumor growth curves and endpoint tumor weight of the two groups of nude mice were monitored and compared.

[0102] Figure 2 This is a graph showing the results of inhibiting PTRHD1 to suppress tumor growth. Figure 2 It can be seen that in immunocompetent mice, the growth rate, tumor volume, and final tumor weight of the PTRHD1-KO group were significantly lower than those of the Ctrl control group; while in immunodeficient nude mice, there was no significant difference in tumor growth between the two groups, indicating that the tumor-suppressive effect of PTRHD1 gene knockout depends on the immune system.

[0103] in, Figure 2 The curve of tumor growth after subcutaneous inoculation of B16-F10 cells into nude mice (SCR group n=6, POOL group n=7) shows no significant difference between the two groups (ns), indicating that PTRHD1 knockout cannot inhibit tumor growth in nude mice with T-cell immunodeficiency. Figure 2 Figure b shows the tumor growth curves of C57BL / 6 immunocompetent mice subcutaneously inoculated with the B16-F10 cell line (SCR group n=6, POOL group n=6, KO#5 group n=6), and the Panc02 cell line (SCR group n=6, KO#1 group n=5, KO#6 group n=5) on the right. Tumor growth was significantly inhibited in all knockout groups (p<0.01 to p<0.0001). Figure 2 c represents the tumor growth curve of 4T1 cells subcutaneously inoculated into Balb / c mice (SCR group n=8, KO group n=8). Tumor growth in the knockout group was significantly inhibited (p<0.0001).

[0104] Example 3 To further validate the potential of the PTRHD1 gene as a sensitizing target for immunotherapy, this embodiment evaluated the therapeutic effect of combining PTRHD1 gene knockout with immune checkpoint inhibitors (anti-PD-1 antibodies) in various tumor models, and conducted in-depth analysis of changes in the tumor immune microenvironment using flow cytometry and single-cell sequencing technologies.

[0105] The specific experimental steps are as follows: 1. In vivo combination therapy experimental design and execution 1.1. Tumor Model Construction: Mouse B16-F10 melanoma, Panc02 pancreatic cancer, and 4T1 breast cancer cell lines were selected. Cells in logarithmic growth phase were resuspended in PBS and subcutaneously inoculated into the right inguinal region of immunized mice (C57BL / 6 mice were used for B16-F10 and Panc02 models, and BALB / c mice were used for the 4T1 model).

[0106] 1.2. Grouping of experimental animals: After the tumor becomes palpable (usually 5-7 days after inoculation, with a volume of approximately 50-100 mm³), the tumor-bearing mice are randomly divided into the following four groups (n≥5): Group 1 (IgG control group): Ctrl cells were inoculated and intraperitoneal injection of isotype control IgG antibody was administered.

[0107] Group 2 (anti-PD-1 group only): Ctrl cell inoculation + intraperitoneal injection of anti-PD-1 monoclonal antibody.

[0108] Group 3 (simple knockout group): PTRHD1-KO cells were inoculated and intraperitoneal injection of isotype control IgG antibody was administered.

[0109] Group 4 (Combined Treatment Group): PTRHD1-KO cells were injected and anti-PD-1 monoclonal antibody was injected intraperitoneally.

[0110] 1.3. Dosing regimen: The corresponding antibody (anti-PD-1 or isotype control IgG) was administered intraperitoneally at the predetermined dose (e.g., 200 µg / time / mouse) and frequency (e.g., once every other day for a total of 5 times). Simultaneously, the long and short diameters of the tumor were periodically measured using electronic calipers, the tumor volume was calculated, and the mouse weight was recorded.

[0111] 1.4. Experimental endpoint and sample collection: a. Tumor growth monitoring: Continuously monitor tumor volume, plot growth curves, and compare the growth inhibition of tumors in each group.

[0112] b. Survival analysis: For survival experiments, the endpoint was defined as the tumor volume exceeding ethical limits (e.g., 2000 mm³) or the mice becoming terminally ill. Survival time was recorded, Kaplan-Meier survival curves were plotted, and Log-rank tests were performed.

[0113] c. Tissue Collection: After treatment (or at a designated time point), mice were euthanized and tumor tissue was removed. A portion of the tumor tissue was immediately used for subsequent flow cytometry and single-cell sequencing analysis, while the remainder was stored in liquid nitrogen or at -80°C.

[0114] Figure 3 This is a graph showing the results of inhibiting PTRHD1 to enhance the tumor's response to anti-PD-1 therapy. Figure 3 It can be seen that the tumor growth inhibition rate of the PTRHD1-KO combined with anti-PD-1 antibody treatment group was significantly higher than that of the anti-PD-1 group and the knockout group alone, and the median survival of mice was significantly prolonged, indicating that the combination of PTRHD1 gene knockout and anti-PD-1 antibody has a synergistic anti-tumor effect.

[0115] in, Figure 3 In Figure 'a', tumor growth curves and drug administration timelines are shown for four groups after subcutaneous inoculation of B16-F10 cells into C57BL / 6 mice (SCR + isotype control antibody group n=10, KO + isotype control antibody group n=10, SCR + anti-PD-1 antibody group n=12, KO + anti-PD-1 antibody group n=12; cells were inoculated on day 0, and isotype control antibody or anti-PD-1 antibody was administered on days 4 and 10). The tumor volume in the KO + anti-PD-1 combined treatment group was significantly smaller than that in the other groups (p<0.0001), while there was no significant difference between the SCR + isotype control antibody group and the KO + isotype control antibody group (ns). Figure 3 b represents the cumulative survival analysis (Kaplan-Meier curve) of the four groups of mice. The survival of mice in the KO + anti-PD-1 combination therapy group was significantly prolonged.

[0116] 2. Flow cytometry analysis of the tumor immune microenvironment 2.1. Preparation of single-cell suspension: Fresh tumor tissue was placed in a digestion solution containing collagenase IV and DNase I and digested with shaking at 37°C for 30-45 minutes. After digestion, the suspension was filtered through a 70μm cell filter to obtain a single-cell suspension. Red blood cells were removed using red blood cell lysis buffer, and the cells were resuspended in PBS for viable cell counting.

[0117] 2.2. Cell surface staining: Take an appropriate amount of single-cell suspension, first block it with anti-mouse CD16 / 32 antibody (Fc receptor blocker), then add multicolor flow cytometry antibody mixture (targeting the following markers: CD45, CD3, CD4, CD8, NK1.1, etc.), and incubate at 4°C in the dark for 30 minutes. Wash with flow cytometry staining buffer after staining.

[0118] 2.3. Flow Cytometry Detection and Analysis: Data was acquired using a flow cytometer. Analysis was performed using software such as FlowJo, with the following gating strategy: first, viable cells were delineated (based on live / dead staining) and CD4 counts were determined. + White blood cells, and then analyze CD3 in them + CD8 + Cytotoxic T cells, CD3 + CD4 + Helper T cells and CD3 - NK 1.1 + The proportion and absolute number of natural killer cells were compared. Differences in the infiltration of these key immune cell subsets were also compared among the experimental groups.

[0119] 3. Single-cell transcriptome sequencing analysis of the tumor immune microenvironment 3.1. Sample Preparation and Library Construction: Tumor tissues were selected from the "Combination Therapy Group" (PTRHD1-KO + Anti-PD-1) and other key control groups (such as the IgG control group), and high-quality single-cell suspensions were prepared according to step 2.1. Using the 10xGenomics platform, single cells were mixed with gel beads and library construction reagents according to the Chromium Next GEM Single Cell 5' Kit Instructions to construct a single-cell RNA sequencing library.

[0120] 3.2. Sequencing: The constructed library was sequenced on a high-throughput sequencer such as Illumina NovaSeq 6000 to obtain gene expression data for each cell.

[0121] 3.3. Bioinformatics Analysis: a. Data preprocessing: Cell Ranger software was used to align and count the raw sequencing data to generate a gene-cell expression matrix.

[0122] b. Cell Clustering and Annotation: Data analysis was performed using R / Python packages such as Seurat or Scanpy. Steps included: quality control filtering, data normalization, principal component analysis, graph-based cell clustering, and UMAP / t-SNE dimensionality reduction visualization. Cell clusters were annotated based on known cell marker genes (such as Cd3e, Cd8a, Cd4, Nkg7, Klrb1c, etc.) to identify major cell groups such as T cells, NK cells, macrophages, and tumor cells.

[0123] c. Comparative analysis: Compare the changes in the proportion of each cell group (especially T cells and NK cells) in the total cells and the transcriptome differences within each subgroup between the combined treatment group and the control group, so as to analyze the remodeling of the immune microenvironment at single-cell resolution.

[0124] Figure 4 This is a diagram showing the effect of PTRHD1 deficiency promoting the infiltration of cytotoxic immune cells in the tumor microenvironment. Figure 4 It can be seen that the infiltration ratio and absolute number of cytotoxic immune cells such as CD8+ T cells and NK cells in the PTRHD1-KO tumor (and combination therapy group) microenvironment were significantly increased, indicating that PTRHD1 deficiency can reshape the tumor immune microenvironment and promote the infiltration of cytotoxic immune cells.

[0125] in, Figure 4 'a' is a scatter plot of flow cytometry dimensionality reduction analysis, comparing the overall distribution of tumor-infiltrating immune cells (cell populations including CD45+ T cells, NK cells, T cells, CD8+ T cells, CD107+CD8+ T cells, CD4+ T cells and CD25+CD4+ T cells) between the SCR-anti-PD-1 antibody group and the KO-anti-PD-1 antibody group. Figure 4 b represents a comparison of the percentage of CD4+T, CD8+T, NK, and CD107+CD8+T cells among the viable cells in the two groups. The proportion of each subset was significantly increased in the KO group (p<0.05). Figure 4 c represents the comparison of the absolute number of the above-mentioned immune cell subsets per gram of tumor tissue, and all of them were significantly increased in the KO group (p<0.05 to p<0.01). Figure 4 d represents the immunohistochemical staining images of tumor tissue sections from the two groups. The number of positive immune cells infiltrating the tumor in the KO group was significantly increased. Figure 4 e represents the UMAP dimensionality reduction plot of single-cell transcriptome sequencing (Ptrhd1 KO group: 60,917 cells; Scramble control group: 15,238 cells). Figure 4 f represents the UMAP clustering results and cell type annotations (including T cells, NK cells, B cells, macrophages, granulocytes, plasmacytoid dendritic cells, myeloid dendritic cells, mDC, pDC, platelets, and fibroblasts, etc.). Figure 4 The 'g' plot represents the percentage of each cell group in the Scramble and Ptrhd1 KO groups. The percentage of T cells and other lymphocytes is increased in the KO group.

[0126] Example 4 Given that the PTRHD1 protein is located in mitochondria, we systematically evaluated the effects of PTRHD1 gene knockout on mitochondrial function, morphology, and cell death patterns, and validated its association with an immune-enhancing phenotype.

[0127] The specific experimental steps are as follows: 1. Mitochondrial membrane potential detection 1.1. JC-1 staining method for detecting membrane potential: a. Cell preparation and grouping: Wild-type (WT) and PTRHD1 gene knockout (PTRHD1-KO) Panc02 cells were seeded at an appropriate density in 96-well plates with black transparent bottoms or 24-well plates with coverslips, and cultured overnight to allow the cells to adhere.

[0128] b. Probe loading: Discard the original culture medium, add JC-1 working solution diluted with serum-free culture medium according to the instructions, and incubate in a 37°C, 5% CO2 cell culture incubator in the dark for 20-30 minutes.

[0129] c. Washing and observation: After incubation, gently wash the cells 2-3 times with preheated JC-1 staining buffer or PBS.

[0130] d. Fluorescence detection: Fluorescence microscopy observation: Observe immediately under a fluorescence microscope. Take pictures using excitation / emission light suitable for detecting JC-1 polymers (J-aggregates) (e.g., Ex / Em=525 / 590 nm, red fluorescence) and excitation / emission light suitable for detecting JC-1 monomers (e.g., Ex / Em=490 / 530 nm, green fluorescence), respectively. Compare the ratio of red to green fluorescence in WT and PTRHD1-KO cells.

[0131] Flow cytometry or ELISA reader quantification: Digest and resuspend cells (for flow cytometry) or add buffer directly to the well plate (for ELISA reader). Use a flow cytometer or multi-channel ELISA reader to detect the fluorescence intensity of the red and green channels. Calculate the red-green fluorescence intensity ratio; a decrease in this ratio indicates a decrease in mitochondrial membrane potential.

[0132] 1.2. MitoTracker staining verification: a. Seed WT and PTRHD1-KO B16-F10 cells in confocal culture dishes.

[0133] b. Stain using MitoTracker Deep Red FM (or other types). Discard the old medium, add complete medium containing the pre-working concentration of MitoTracker dye, and incubate at 37°C in the dark for 15-30 minutes.

[0134] c. After incubation, wash the cells three times with preheated PBS. Counterstain with culture medium containing Hoechst 33342 (nuclear dye) for 10-15 minutes. After washing, observe mitochondrial morphology and fluorescence intensity under a confocal microscope and perform quantitative image analysis.

[0135] 2. Observation of mitochondrial ultrastructure (transmission electron microscopy) 2.1. Pre-sample fixation: Collect B16-F10 WT and PTRHD1-KO cells in the logarithmic growth phase, digest with trypsin, and centrifuge to form clumps. Carefully discard the supernatant and gently resuspend once in pre-chilled 0.1 M phosphate buffer (PB, pH 7.4). Immediately after centrifugation, add 2.5% glutaraldehyde (prepared with 0.1 M PB) fixative and fix at 4°C for at least 2 hours or overnight.

[0136] 2.2. Sample fixation and dehydration: a. Rinse the fixed cell clumps three times with 0.1 M PB for 15 minutes each time.

[0137] b. Fix with 1% osmium tetroxide (prepared with 0.1 M PB) at 4°C in the dark for 1-2 hours.

[0138] c. After rinsing three times with 0.1 M PB, dehydrate using gradient concentrations of ethanol (50%, 70%, 80%, 90%, 95%, 100%) for 15-20 minutes at each concentration, and repeat once with anhydrous ethanol.

[0139] 2.3. Infiltration, Encapsulation, and Polymerization: a. Permeate the sample with a mixture of epoxy resin (such as Epon 812) and anhydrous ethanol (1:1, 2:1) for 1-2 hours each time, and finally permeate with pure resin overnight at room temperature.

[0140] b. Transfer the sample into an embedding plate that has been injected with fresh resin, adjust the sample position, and place it in a 60°C oven for polymerization for 48 hours.

[0141] 2.4. Ultrathin Sectioning and Staining: The sample block was cut into ultrathin sections of 60-80 nm thickness using an ultramicrotome and retrieved using a copper mesh. The sections were then subjected to double electron staining with uranyl acetate and lead citrate solutions, each for 5-10 minutes, and dried.

[0142] 2.5. Electron Microscopy Observation and Image Acquisition: The prepared copper mesh was placed under a transmission electron microscope and the internal structure of the cells was observed at an appropriate magnification (e.g., ×8,000 - ×30,000). The focus was on finding and photographing mitochondria, and comparing the differences in morphology, size, cristae structure, etc. of mitochondria between WT and PTRHD1-KO cells.

[0143] 3. Apoptosis detection (flow cytometry) 3.1. Cell Treatment and Grouping: B16-F10 and Panc02 WT and PTRHD1-KO cells were seeded in 6-well plates. The experiment was divided into the following groups: Resting state group: Cells were cultured normally in complete culture medium.

[0144] Cytokine stimulation group: Cells were replaced with complete culture medium containing TNF-α and IFN-γ (e.g., 20 ng / mL each) and stimulated for a certain period of time (e.g., 24 hours).

[0145] 3.2. Cell Collection and Staining: a. After processing, collect all cells (including floating cells in the supernatant and adherent cells after trypsin digestion), combine them, and centrifuge.

[0146] b. Wash the cells once with pre-cooled PBS, centrifuge and discard the supernatant.

[0147] c. Follow the instructions for the Annexin V-FITC / PI apoptosis detection kit: Resuspend cells in 100-200 µL of 1× Binding Buffer, add an appropriate amount of Annexin V-FITC and propidium iodide (PI) staining solution, mix gently, and incubate at room temperature in the dark for 15-20 minutes.

[0148] 3.3. Flow Cytometry Detection and Analysis: Immediately after incubation, an appropriate amount of 1× Binding Buffer was added, and flow cytometry was used for detection within 1 hour. Fluorescence signals were collected through the FITC channel (Annexin V) and the PE or PerCP channel (PI). Data were analyzed using FlowJo software, and a four-quadrant diagram was used to distinguish live cells (Annexin V- / PI-), early apoptotic cells (Annexin V+ / PI-), late apoptotic / necrotic cells (Annexin V+ / PI+), and dead cells (Annexin V- / PI+). The total apoptosis rate (early apoptosis rate + late apoptosis rate) of each group was calculated, and the difference in apoptosis rate between WT and PTRHD1-KO cells under cytokine stimulation was compared.

[0149] Figure 5This is a diagram showing the results of PTRHD1 gene deletion inducing mitochondrial dysfunction and cell death. Figure 5 It can be seen that, compared with WT cells, PTRHD1-KO cells showed significantly reduced mitochondrial membrane potential, abnormal mitochondrial morphology, and damaged cristae structure. At the same time, the apoptosis and necrosis rates were significantly increased under cytokine stimulation, indicating that PTRHD1 deficiency promotes cell death by inducing mitochondrial dysfunction.

[0150] in, Figure 5 a represents the curves showing the change in the number of viable cells in the B16-F10 and Panc02 cell lines over time under DMSO or TNFα+IFN-γ stimulation (SCR-DMSO group, KO-DMSO group, SCR-TNFα+IFN-γ group, KO-TNFα+IFN-γ group). There was no significant difference between the two groups in the DMSO treatment group (ns). After TNFα+IFN-γ stimulation, the number of viable cells in the PTRHD1-KO group was significantly lower than that in the SCR group (p<0.0001). Figure 5 b represents the four-quadrant diagram of apoptosis detection and the bar chart of quantitative cell death by flow cytometry after Annexin V-FITC / PI double staining (B16-SCR, B16-KO, Panc02-SCR, and Panc02-KO groups). There was no significant difference among the DMSO treatment groups (ns). The proportion of cell death in the KO group was significantly increased under IFNγ+TNFα stimulation (p<0.0001).

[0151] Example 5 This embodiment aims to translate this basic research finding into a therapeutic strategy. This application embodiment develops a small interfering RNA drug targeting the PTRHD1 gene and delivers it using lipid nanoparticles. The antitumor efficacy and preliminary mechanism of this drug, both as a monotherapy and in combination with an anti-PD-1 antibody, are evaluated in a subcutaneous tumor-bearing mouse model.

[0152] The specific experimental steps are as follows: 1. Design, screening, and LNP preparation of siRNA 1.1. siRNA Design and Synthesis: Multiple (usually 3-5) small interfering RNA (siRNA) molecules were designed and chemically synthesized targeting the mouse PTRHD1 gene mRNA sequence. Simultaneously, a sequence with no significant homology to any mouse gene was designed as a negative control (siNC).

[0153] 1.2. Screening for in vitro silencing efficiency: a. The designed and synthesized siRNA molecules were transfected into mouse B16-F10 melanoma cells and Panc02 pancreatic cancer cells, respectively, using liposome transfection reagent.

[0154] b. 48-72 hours after transfection, cells were collected and the expression level of PTRHD1 mRNA was detected by real-time quantitative PCR (qRT-PCR).

[0155] c. Select the siRNA with the highest silencing efficiency (usually >80%) and the lowest off-target risk predicted by bioinformatics, name it siPTRHD1, and use it for subsequent experiments. At the same time, determine the negative control siNC.

[0156] 1.3. LNP Packaging and Characterization: a. LNP preparation: Using microfluidic mixing technology, the screened siPTRHD1 (or control siNC) was mixed with ionizable lipids, cofactor phospholipids, cholesterol and PEGylated lipids in an optimized ratio to prepare lipid nanoparticles (LNPs) encapsulating siRNA, which were denoted as siPTRHD1-LNP and empty LNP (encapsulated siNC or without nucleic acid), respectively.

[0157] b. Physicochemical characterization: The hydration kinetics, particle size, and polydispersity index of LNPs were measured using a dynamic light scattering analyzer. The surface potential was measured using a zeta potential analyzer. The encapsulation efficiency of siRNA was determined using dye repulsion assay or high-performance liquid chromatography. The stability of LNPs in serum was assessed.

[0158] 2. In vivo pharmacodynamic evaluation 2.1. Animal Model Establishment and Grouping: a. Take homogeneous immune healthy mice (such as C57BL / 6) and subcutaneously inoculate them with B16-F10 cells to establish a subcutaneous melanoma tumor-bearing model.

[0159] b. When the tumor volume grows to approximately 50-100 mm³, the tumor-bearing mice are randomly divided into the following four groups (n=8-10): Group 1 (control group): Injection of empty LNP + intraperitoneal injection of isotype control IgG antibody.

[0160] Group 2 (anti-PD-1 monotherapy group): injection of empty LNP + intraperitoneal injection of anti-PD-1 antibody.

[0161] Group 3 (siPTRHD1-LNP monotherapy group): siPTRHD1-LNP injection + intraperitoneal injection of isotype control IgG antibody.

[0162] Group 4 (Combined Treatment Group): Injection of siPTRHD1-LNP + intraperitoneal injection of anti-PD-1 antibody.

[0163] 2.2. Dosing regimen: a. LNP (siPTRHD1-LNP or empty LNP) is administered via peritumoral injection or intravenous injection at a dose of X mg siRNA / kg body weight, once every 3-4 days, for a total of 3-4 doses.

[0164] b. Anti-PD-1 antibody or its isotype control IgG was administered via intraperitoneal injection at a dose of Y µg / animal, with the administration frequency synchronized with LNP.

[0165] c. Periodically measure the long and short diameters of the tumor using vernier calipers, calculate the tumor volume, and record the mouse's weight.

[0166] 2.3. Efficacy assessment: a. Tumor growth inhibition: Plot the growth curves of tumor volume changes over time in each group of mice, and compare the differences in tumor volume and tumor inhibition rate among the groups at the treatment endpoint.

[0167] b. Survival analysis: The survival time of mice was recorded when the tumor volume exceeded 2000 mm³ or the mice became terminally ill. Kaplan-Meier survival curves were plotted, and the Log-rank test was used to compare the differences in survival time among the groups.

[0168] 3. Validation of drug efficacy and mechanism 3.1. Validation of PTRHD1 gene knockdown efficiency in tumors: a. qRT-PCR validation: 24-48 hours after the last administration, some mice were sacrificed, and tumor tissue was dissected. Total RNA was extracted from the tumor tissue and reverse transcribed into cDNA. qRT-PCR analysis was performed using specific primers targeting PTRHD1 and internal reference genes (such as Gapdh), and the relative expression level of PTRHD1 mRNA in each tumor group was calculated.

[0169] b. Immunofluorescence / immunohistochemical verification: Frozen or paraffin sections were prepared from a portion of the tumor tissue. Immunofluorescence / immunohistochemical staining was performed, using anti-PTRHD1 antibody and tumor cell marker antibody (such as broad-spectrum cytokeratin Pan-CK) for co-staining. The expression level of PTRHD1 protein in the tumor area was observed and quantitatively analyzed using a fluorescence microscope or pathological scanning system.

[0170] 3.2. Preliminary security assessment: a. Weight monitoring: Throughout the treatment period, the weight of mice in each group was weighed and recorded regularly, and weight change curves were plotted to assess the systemic toxicity of the treatment.

[0171] b. Histopathological analysis: After the experiment, the major organs (heart, liver, spleen, lung, and kidney) of the mice were collected, fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). The tissue structure of each organ was observed under an optical microscope to check for pathological changes related to treatment, such as inflammation, necrosis, and vacuolar degeneration.

[0172] Figure 6 This is a graph showing the evaluation results of the antitumor efficacy of siRNA-LNP drugs targeting the PTRHD1 gene combined with PD-1 blockers. Figure 6 It can be seen that the tumor growth in the siPTRHD1-LNP combined with anti-PD-1 antibody treatment group was strongly inhibited and even partially regressed, and the survival time of mice was significantly prolonged. Its efficacy was significantly better than that of each single drug treatment group, indicating that the combination of PTRHD1-targeting siRNA-LNP drug and anti-PD-1 antibody has good anti-tumor efficacy.

[0173] in, Figure 6 Figure 'a' shows the tumor growth curves and drug administration timelines for the four groups of tumor-bearing mice (siCtrl + isotype control antibody group n=5, siPtrhd1 + isotype control antibody group n=5, siCtrl + anti-PD-1 antibody group n=5, siPtrhd1 + anti-PD-1 antibody group n=5; cells were inoculated on day 0, and Control or Ptrhd1 siRNA was injected on days 6, 9, 12, 15, and 18, and isotype control antibody or anti-PD-1 antibody was administered on the same day). Tumor growth was significantly inhibited in the siPtrhd1 + anti-PD-1 combined treatment group (p<0.0001). Figure 6 b represents the actual photos of the dissected tumors in each group at the experimental endpoint, with the siPtrhd1+ anti-PD-1 group having the smallest tumor mass. Figure 6 c is a flow cytometry dimensionality reduction scatter plot of four groups of tumor-infiltrating immune cells (cell populations include CD45+ T cells, B cells, T cells, NK cells, CD8+ T cells and CD4+ T cells). Figure 6 d represents the comparison of the percentage of CD4+ T cells, CD8+ T cells, and NK cells among the four tumor groups. The proportion of CD4+ T cells in the siPtrhd1+ anti-PD-1 group was significantly higher (p<0.001), and the proportion of NK cells was also significantly higher than that in the siCtrl+ isotype control group (p<0.01).

[0174] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. An application of PTRHD1 as a target site for tumor immunotherapy, characterized in that, The PTRHD1 protein contains the amino acid sequence shown in SEQ ID No. 1, or a protein that has at least 85% amino acid sequence identity with SEQ ID No.

1.

2. The application of PTRHD1 as a target site for tumor immunotherapy according to claim 1, characterized in that, The PTRHD1 protein also includes the amino acid sequence shown in SEQ ID No.

2.

3. The application of PTRHD1 as a target site for tumor immunotherapy according to claim 1 or 2, characterized in that, The PTRHD1 protein is encoded by either the mouse mRNA sequence shown in SEQ ID No. 3 or the human mRNA sequence shown in SEQ ID No.

4.

4. The application of PTRHD1 as a target site for tumor immunotherapy according to claim 1, characterized in that, The applications include: using PTRHD1 as a tumor immunotherapy target to prepare drugs for the prevention or treatment of tumors; and / or using PTRHD1 as a tumor immunotherapy target to activate cytotoxic immune cells in immunotherapy.

5. The application of PTRHD1 as a target site for tumor immunotherapy according to claim 4, characterized in that, The cytotoxic immune cells include NK cells and CD8 cells. + At least one of the following in T cells.

6. The application of PTRHD1 as a target site for tumor immunotherapy according to any one of claims 1-5, characterized in that, The mechanism by which PTRHD1 is used as a target for tumor immunotherapy is as follows: by inhibiting the expression of PTRHD1, the function of the PGAM5 / DRP1 axis is regulated, which promotes excessive division of mitochondria in tumor cells, leading to non-programmed necrosis and apoptosis. The occurrence of tumor cell necrosis and apoptosis promotes the improvement of the tumor immune microenvironment, while enhancing the inflammatory immunogenicity of cells and thereby activating cytotoxic immune cells to exert their effects.

7. The application of PTRHD1 as a target site for tumor immunotherapy according to any one of claims 1-4, characterized in that, The tumors include primary tumors and metastatic tumors.

8. A drug for tumor immunotherapy, characterized in that, The drug is a drug that inhibits the expression of PTRHD1 protein or reduces the activity of PTRHD1 protein, wherein the PTRHD1 protein contains the amino acid sequence shown in SEQ ID No. 1, or has at least 85% amino acid sequence identity with SEQ ID No.

1.

9. The medicament for tumor immunotherapy according to claim 8, characterized in that, The drug comprises siRNA that targets the mRNA encoding the PTRHD1 protein and lipid nanoparticles that deliver the siRNA, forming an siRNA-LNP complex.

10. The medicament for tumor immunotherapy according to claim 9, characterized in that, The siRNA contains chemical modifications selected from one or more of 2'-O-methyl modification, 2'-fluorine modification, thiophosphate bond modification, or 5'-terminal cholesterol modification; and / or, the lipid nanoparticles contain ionizable cationic lipids, auxiliary lipids, cholesterol, and polyethylene glycol-modified lipids.